Radiation Oncology

Gastric/GEJ Cancer

Questions discussed in this category

What are your top takeaways from ASCO GI 2026?

What are your top takeaways in GI Cancers from ESMO 2025?

In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?

Patient has a cluster of retroperitoneal lymph nodes. The RP area would be initially contiguous with the radiation field, but does extend inferior to ...

5 Answers available

What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?

3 Answers available

What are your top takeaways from ASCO GI 2025?

8 Answers available

What are your top takeaways from ASCO GI 2023?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

8 Answers available

What are your top takeaways in GI Cancers from ASCO 2023?

6 Answers available

Papers discussed in this category

The New England journal of medicine, 2013-10-31

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N. Engl. J. Med.,

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Eur J Cancer, 2018 Aug 24

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

N Engl J Med, 2023 Jun 04

Preoperative Treatment of Locally Advanced Rectal Cancer.

Lancet Oncol, 2021 May 04

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Lancet Oncol, 2023 Jun 02

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

N. Engl. J. Med., 2019 Sep 30

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med,

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

JAMA oncology, 2020 Jul 01

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

The New England journal of medicine, 2025 Sep 18

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.

Future oncology (London, England), 2025 Nov 13

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.

Lancet (London, England), 2025 Oct 20

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Radiation Oncology

Gastric/GEJ Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology